Efficacy of MitoHeal supplementation on adult skin quality and patient satisfaction: a randomized, double-blind, placebo-controlled, pilot study

Performed at Jacksonville University

A 30-day randomized, placebo-controlled study, with 40 adults (mean age 44.65 years) were randomized to one of three groups: MitoHeal 500 mg/day, MitoHeal 1000 mg/day or placebo drink. Measurements included expert ratings of professional photos of skin quality and patient self-reported skin satisfaction at Days 0 and 30. The photographs and self-report assessments revealed that, compared with placebo, MitoHeal supplementation resulted in improvements in skin quality and patient satisfaction from Day 0 to Day 30, with a dose–response relationship often
evidenced (P < 0.05). No adverse events were reported.

Hooper S, Hausenblas HA, Winters C. Efficacy of MitoHeal^® supplementation on adult skin quality and patient satisfaction: a randomized, double-blind, placebo-controlled, pilot study. Clin Exp Dermatol. 2022 Dec;47(12):2269-2272. doi: 10.1111/ced.15371. Epub 2022 Oct 4. PMID: 35973827; PMCID: PMC10092201.

https://pubmed.ncbi.nlm.nih.gov/35973827